Sanara MedTech Inc. (NASDAQ:SMTI) reported fourth-quarter results on Tuesday that came in below analyst expectations while reaffirming its revenue outlook for 2026. Despite the miss, the company’s shares climbed 3.44% in after-hours trading following the announcement.
The medical technology company posted a quarterly loss of -$0.19 per share, missing the analyst consensus estimate of $0.33 by $0.52. Revenue totaled $27.5 million, slightly below the $27.78 million consensus estimate but still up 5% from $26.3 million in the same quarter a year earlier.
When excluding approximately $1.8 million in extraordinary BIASURGE sales recorded in the fourth quarter of 2024 due to supply chain disruptions caused by Hurricane Helene, revenue increased 13% year over year.
For the full year 2025, Sanara reported revenue of $103.1 million, representing a 19% increase compared with $86.7 million in 2024.
The company maintained its 2026 revenue guidance of $116 million to $121 million, which would represent growth of 13% to 17%. The midpoint of the range, $118.5 million, points to continued expansion in the surgical products market.
“We are pleased to deliver strong sales performance in 2025, achieving our first full year of net revenue in excess of $100 million, with 19% growth year-over-year,” said Seth Yon, President and Chief Executive Officer.
Gross margin in the fourth quarter improved to 93% from 91% in the prior-year period, driven by stronger sales of soft tissue repair products and lower manufacturing costs for CellerateRX Surgical.
However, operating expenses rose 13% year over year to $24.6 million, including a $1.8 million non-cash asset impairment charge related to intellectual property write-downs.